News|Articles|May 13, 2026

DDW 2026 Recap: 5 Trials to Know

Catch up on 5 notable studies and trial updates from DDW 2026!

Digestive Disease Week (DDW) 2026 featured a wave of new data across inflammatory bowel disease (IBD), eosinophilic esophagitis (EoE), and irritable bowel syndrome (IBS), with investigators highlighting advances in disease modification, long-term durability, and emerging therapeutic mechanisms. From phase 3 fistulizing Crohn disease data to early evidence supporting varenicline in IBS, this year’s meeting delivered several studies with potential implications for clinical practice.

Related to this article

September 24th, 2026

The Medical Sisterhood: Is Becoming a Doctor Still Worth It?

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.

September 24th, 2026

Q&A: Clinician Investing and Injection Anxiety, With Manju Dawkins, MD

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

September 23rd, 2026

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.

September 23rd, 2026

Conference Preview: 2026 EADV Congress in Vienna

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

September 22nd, 2026

Skin of Color Savvy: How SOCS Serves Builds Dermatology Pathways and Community Trust

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.

September 26th, 2026

Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry

Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

September 26th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

September 25th, 2026

FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.